GoodRx (NASDAQ:GDRX) Shares Down 5.7% - Here's Why

Key Points

• Shares fell 5.7% to about $2.07 on Monday, trading as low as $2.08 on light volume (down ~89% vs. average) and sitting below its 50‑day ($2.18) and 200‑day ($2.81) moving averages.
• Analysts are mixed and have cut targets — GoodRx has an average rating of "Hold" with an average price target of $3.85, and recent cuts include Wells Fargo (from $7.00 to $3.50) and Morgan Stanley (to $4.00).
• Recent quarterly results met expectations: GoodRx reported $0.09 EPS and $194.8M revenue (down 1.9% year‑over‑year), with a market cap around $742M and institutional ownership of ~63.8%.

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) dropped 5.7% on Monday . The company traded as low as $2.08 and last traded at $2.0650. Approximately 323,326 shares changed hands during trading, a decline of 89% from the average daily volume of 2,845,478 shares. The stock had previously closed at $2.19.

Wall Street Analyst Weigh In

GDRX has been the topic of a number of research analyst reports. Wall Street Zen downgraded GoodRx from a "buy" rating to a "hold" rating in a report on Sunday, January 25th. Weiss Ratings reiterated a "sell (d)" rating on shares of GoodRx in a report on Tuesday, December 23rd. Wells Fargo & Company reduced their target price on GoodRx from $7.00 to $3.50 and set an "overweight" rating on the stock in a report on Wednesday, March 4th. Morgan Stanley reduced their target price on GoodRx from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Thursday, December 18th. Finally, Citigroup reduced their target price on GoodRx from $4.50 to $3.50 and set a "buy" rating on the stock in a report on Tuesday, March 3rd. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $3.85.

GoodRx Stock Performance

The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.61 and a current ratio of 2.61. The business has a 50-day moving average price of $2.18 and a 200 day moving average price of $2.81. The stock has a market capitalization of $741.66 million, a P/E ratio of 24.17, a PEG ratio of 1.51 and a beta of 1.47.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, hitting analysts' consensus estimates of $0.09. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The firm had revenue of $194.79 million for the quarter, compared to analysts' expectations of $193.27 million. During the same period in the previous year, the firm posted $0.09 EPS. The business's revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On GoodRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC lifted its position in GoodRx by 43.6% in the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock valued at $85,000 after acquiring an additional 5,201 shares in the last quarter. Brevan Howard Capital Management LP lifted its position in GoodRx by 7.7% in the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company's stock valued at $404,000 after acquiring an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC lifted its position in GoodRx by 60.3% in the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company's stock valued at $49,000 after acquiring an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after acquiring an additional 7,580 shares in the last quarter. Finally, Quarry LP bought a new position in GoodRx in the 3rd quarter valued at approximately $33,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.